Diovan Clinical Trials

Browse 22 Diovan Medical Studies Across 154 Cities

5 Phase 3 Trial · 205 Diovan Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates

Aliskiren + Valsartanfor Diabetes Mellitus

Baltimore, MD
All Sexes
People with both hypertension and diabetes have a higher chance of developing heart and arterial problems that could be reduced with anti-coagulant therapy. Valsartan (Diovan), an FDA approved angiotensin-II receptor antagonist (blocker) clinically indicated for the treatment of essential hypertension is known to inhibit platelet activity in both an in vitro and ex vivo setting. Aliskiren (Tekturna) is a recently FDA-approved potent direct renin inhibitor which is also an effective anti-hypertensive agent in patients with mild-to-moderate hypertension and which, in vitro, modulates antithrombin III in plasma. Therefore, in addition to being clinically approved anti-hypertensive medications, combining these two agents will potentially target both primary hemostasis (platelets) and anticoagulant (antithrombin-III is a cornerstone substrate for heparin) properties to exert their anti-thrombotic efficacy simultaneously. This combination strategy may not only improve hypertension management, but also improve vascular outcomes in high-risk diabetic population via favorable effects on anti-thrombotic activity. Importantly, there have been no significant additional safety concerns of using the combination of aliskiren and valsartan. The investigators hypothesis is that valsartan 160 mg/daily in combination with aliskiren 150-300 mg/daily for 4 weeks will favorably affect blood levels of platelet/coagulation/fibrinolytic biomarkers (ie, diminish platelet activity, and enhance antithrombin III potency) when compared with monotherapy with aliskiren 150mg/daily in hypertensive patients with type 2 diabetes mellitus.
Phase 4
Waitlist Available
22 Diovan Clinical Trials Near Me
Rochester, MN
Richmond, VA
Montreal, Canada
Oak Brook, IL
More Trial Locations
An interactive map to display trial locations for Mayo Clinic in Rochester, Virginia Commonwealth University, Montreal Heart Institute, Research Site, and 56 more locations.
Most Popular References for Diovan Clinical Trials
Top Cities for Diovan Clinical Trials
Active Diovan Clinical Trials
Top Active Site for Diovan Clinical Trials
Trial List
Hamilton, Ontario
Novartis Investigative Site
Winnipeg, Manitoba
Novartis Investigative Site
Montréal, Quebec
McGill University Health Centre
Most Recent Diovan Clinical Trials
Phase 3 Diovan Clinical Trials
Pediatric Diovan Clinical Trials
Clinical Trial
Began Recruiting Date
Senior Friendly Diovan Clinical Trials

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: August 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.